The third-generation of in vitro fertilization (IVF) for families with autism spectrum disorder (ASD) involves a complex process that combines genetic testing, embryo selection, and pre-implantation genetic diagnosis (PGD). This article provides a detailed overview of the process, including the screening of genetic markers, the selection of healthy embryos, and the implantation of embryos with a reduced risk of ASD.
自闭症家庭试管婴儿第三代的流程涉及复杂的遗传测试、胚胎筛选和移植前基因诊断（PGD）等过程。本文将详细介绍该流程，包括基因标记的筛选、健康胚胎的选择以及具有较低自闭症风险的胚胎的植入。
The process begins with genetic screening of the parents to identify any known genetic markers associated with ASD. Once the genetic markers are identified, the next step is to create embryos through IVF, and then conduct genetic testing on the embryos to identify those with a reduced risk of ASD.
该流程始于对父母进行基因筛查，以确定与自闭症相关的已知遗传标记。一旦确定了遗传标记，下一步就是通过试管婴儿技术创造胚胎，然后对胚胎进行基因测试，以确定具有较低自闭症风险的胚胎。
The genetic screening process is crucial in identifying the genetic markers associated with ASD and selecting embryos with a reduced risk of developing the disorder.
基因筛查过程至关重要，可以确定与自闭症相关的遗传标记，并选择具有较低发展该疾病风险的胚胎。
Once the embryos are created, they undergo genetic testing to identify those with a reduced risk of ASD. The healthy embryos are then selected for implantation, while those with a higher risk of ASD are discarded.
一旦胚胎被创造出来，它们将接受基因测试，以确定具有较低自闭症风险的胚胎。健康的胚胎将被选中进行植入，而那些患有较高自闭症风险的胚胎将被丢弃。
The selection of embryos with a reduced risk of ASD is a critical step in the process, as it ensures that only healthy embryos are implanted, reducing the likelihood of the child developing ASD.
选择具有较低自闭症风险的胚胎是该流程中的关键步骤，因为这可以确保只有健康的胚胎被植入，降低孩子患上自闭症的可能性。
After the healthy embryos are selected, they undergo pre-implantation genetic diagnosis (PGD) to further confirm their genetic makeup and ensure they are free from any known genetic markers associated with ASD.
在健康的胚胎被选中后，它们将接受移植前基因诊断（PGD），以进一步确认它们的基因构成，并确保它们不携带与自闭症相关的任何已知遗传标记。
PGD is a crucial step in the process, as it provides an additional layer of assurance that the selected embryos are free from any known genetic markers associated with ASD.
PGD是该流程中的关键步骤，因为它提供了额外的保证，确保所选的胚胎不携带与自闭症相关的任何已知遗传标记。
Once the healthy embryos are confirmed to be free from any known genetic markers associated with ASD, they are ready for implantation into the mother's uterus. The implantation process is carefully monitored to ensure the embryos have successfully attached to the uterine wall.
一旦确认健康的胚胎不携带与自闭症相关的任何已知遗传标记，它们就可以植入母亲的子宫。植入过程将得到仔细监控，以确保胚胎成功附着在子宫壁上。
The embryo implantation process is a critical step in the IVF process, as it determines the success of the pregnancy and the likelihood of the child developing ASD.
胚胎植入过程是试管婴儿过程中的关键步骤，它决定了怀孕的成功和孩子患上自闭症的可能性。
After the embryo implantation, the mother undergoes regular monitoring to ensure the pregnancy progresses as expected. This includes regular check-ups and ultrasounds to monitor the growth and development of the fetus.
在胚胎植入后，母亲将接受定期监测，以确保怀孕进展如期。这包括定期检查和超声检查，以监测胎儿的生长和发育。
Post-implantation monitoring is crucial in ensuring the health and development of the fetus, and provides an opportunity to detect any potential issues early on.
植入后监测对确保胎儿的健康和发育至关重要，并提供了及早发现潜在问题的机会。
In conclusion, the third-generation of IVF for families with ASD involves a comprehensive process that includes genetic screening, embryo selection, PGD, embryo implantation, and post-implantation monitoring. This process offers families with a history of ASD the opportunity to reduce the risk of their children developing the disorder, providing hope for a healthier future.